The Medical University of South Carolina (MUSC) Hollings Cancer Center in the US is set to deploy MOLLI Surgical's advanced breast cancer technology, the MOLLI 2 System.

The technology is designed to improve the patient experience and surgical outcomes with its wire-free and radiation-free approach to localising lesions for breast cancer surgery.

It allows radiologists to mark lesions using the MOLLI Marker, a small localisation device that can be placed up to 30 days before surgery.

This flexibility allows radiologists to optimise their time without the need to coordinate with surgical schedules. Surgeons then use the MOLLI Wand and MOLLI Tablet for reliable lesion detection, which eliminates the traditional wire-guided localisation method.

Hollings Comprehensive Breast Program medical director and surgical oncologist Andrea Abbott said: “MOLLI 2 provides precise feedback while localising the lesion; the information is instantaneous and allows for efficiency and accuracy.

“And patients appreciate the flexibility of having the MOLLI Marker placed ahead of time instead of adding another procedure to the day of surgery.”

Designed to offer directional 3D guidance, the technology provides surgeons with millimeter precision in locating the marked lesion.

The MOLLI 2 System's ease of use, reliability, and precision contribute to increased efficiency and an enhanced patient experience.

The integration of the system into the existing workflows and operating rooms at Hollings has been seamless, MOLLI Surgical said.

MOLLI Surgical president and CEO Ananth Ravi said: “MUSC makes a profound impact on its community as the state's only comprehensive academic health system. Given its wide reach to patients and medical students, we're honoured to be selected as a partner to provide precision surgery solutions.

“MUSC's dedication to advancing patient-centric breast cancer care is further affirmed by their adoption of MOLLI 2.”